PLS3 promotes papillary thyroid carcinoma progression by activating the Notch signaling pathway

Thyroid cancer is the most common endocrine malignancy worldwide. Although significant progress has been made in understanding the genetic and molecular alterations that drive thyroid cancer, the mechanisms underlying thyroid tumor progression remain unclear. In this study, we explored the involvement of Plastin-3 (PLS3) in the progression of papillary thyroid cancer and elucidated the underlying molecular mechanisms. We first analyzed clinical samples from papillary thyroid cancer patients and found that PLS3 expression was significantly upregulated in tumor tissues compared to adjacent normal tissues. Moreover, high PLS3 expression was associated with advanced tumor stage and poor prognosis. Further in vitro and in vivo experiments showed that PLS3 could promote the proliferation, migration, and invasive behavior of papillary thyroid cancer cells, while PLS3 knockdown suppressed these processes. Mechanistically, we found that PLS3 promoted papillary thyroid cancer progression by activating the Notch signaling pathway. Specifically, PLS3 upregulated the expression of Notch receptors (Notch1) and downstream target gene (Hes1) in papillary thyroid cancer cells. In summary, our findings collectively indicate that PLS3 plays a pivotal role in driving the progression of papillary thyroid cancer and holds promise as a viable therapeutic target for the treatment of this disease.

Automated summary

This study investigates the role of Plastin-3 (PLS3) in the progression of papillary thyroid cancer and its underlying molecular mechanisms. The expression of PLS3 was significantly upregulated in tumor tissues compared to adjacent normal tissues in clinical samples of papillary thyroid cancer patients. High PLS3 expression was associated with advanced tumor stage and poor prognosis. In vitro and in vivo experiments showed that PLS3 promoted the proliferation, migration, and invasive behavior of papillary thyroid cancer cells through the activation of the Notch signaling pathway. The findings suggest that PLS3 could be a potential therapeutic target for the treatment of papillary thyroid cancer.